HealthcareNSE · BSE

RUBICON RESEARCH LIMITED

RUBICON · ISIN INE506V01022

Share price

₹1,326▼ -1.36%

Market capitalisation

₹21848 Cr● Closed

Live from Yahoo Finance. Pulse animates during NSE market hours (9:15–15:30 IST, weekdays).

01 · Key metrics

Market cap

₹21848 Cr

Current price

₹1,326

-1.36% today

52W high

₹1,400

52W low

₹571

Stock P/E

86.5

P/B ratio

31.61

02 · Per share & returns

EPS (TTM)

₹15.33

Book value

₹41.96

ROE

26.97%

ROA

11.74%

Dividend yield

0.11%

Beta

—

03 · Financials (TTM)

By the numbers

Revenue

₹1754 Cr

+43.50% YoY

EBITDA

₹400 Cr

Net profit

₹247 Cr

+96.60% YoY

Profit margin

14.07%

Operating margin

20.71%

Total debt

₹311 Cr

Total cash

₹346 Cr

Debt / equity

0.24x

Current ratio

2.01x

Payout ratio

0.00%

04 · Analyst view

Target price

₹1,175

Upside

-11.39%

Consensus

STRONG BUY

Analysts

05 · Shareholding pattern

Who owns RUBICON?

Promoters
59.86%
Founders & promoter group
Institutions
11.84%
FII + DII
Public
28.30%
Retail & non-institutional

As of 31 Mar 2026 · Source: NSE corporate filings

06 · Registration & listing

On the record

Symbol: RUBICON
Exchange: NSE · BSE
CIN: —
ISIN: INE506V01022
BSE code: 544578
Sector: Healthcare
Industry: Healthcare
Face value: ₹1
Listing date: 15 Oct 2025
Employees: —
Headquarters: Mumbai, India
Website: www.rubicon.co.in

07 · About

What is RUBICON RESEARCH LIMITED?

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabolic, central nervous system, nicotine replacement therapy, and immunosuppressant. The company was incorporated in 1999 and is based in Mumbai, India.

08 · Common questions

Frequently asked

What is the CIN of RUBICON RESEARCH LIMITED?+

The Corporate Identity Number for RUBICON RESEARCH LIMITED is published in the MCA21 corporate master. FinanceCity backfills CIN values during weekly refreshes.

Who are the promoters of RUBICON RESEARCH LIMITED?+

Promoter holding in RUBICON is approximately 59.86%, as disclosed in the latest published shareholding pattern.

What is the market capitalisation of RUBICON RESEARCH LIMITED?+

RUBICON RESEARCH LIMITED (RUBICON) has a market capitalisation of approximately ₹21848 Cr, reflecting the most recent weekly refresh from the BSE scrip master.

09 · Adjacent